GenAns Biotech

About GenAns Biotech

GenAns Biotechnology Co., Ltd. is a privately held, venture-capital-backed gene therapy company founded in 2022 and headquartered in Beijing, China. The firm operates in the biotechnology sector, focusing on the research and development of innovative medicines for genetic, neurological, and ophthalmic diseases with significant unmet medical needs. It has successfully raised capital, including a Pre-A financing round of 100 million yuan, to advance its programs. The company's strategy is built upon three proprietary technology platforms. The AAV High-Throughput Directed Evolution Screening Platform is engineered to develop and assess gene delivery vectors for specific cell or tissue targeting. Its Functional Protein Screening Platform employs rational design and high-throughput screening to identify and optimize proteins for therapeutic use. Complementing these is the Neurological Drug Discovery and Evaluation Platform, which integrates neural circuit research and biomedical data to facilitate drug discovery and evaluation across multiple biological scales. GenAns is advancing multiple investigational new drug pipelines that target major brain diseases, sensory system disorders, and rare diseases. A key asset in its portfolio is GA002, a chemical-genetic gene therapy developed for treating drug-resistant epilepsy. This therapy involves an adeno-associated virus (AAV) vector to deliver an engineered receptor to neurons in the epileptic focus. This receptor remains inactive until an oral small molecule is administered, which then activates the receptor to suppress epileptic electrical activity, offering a controllable and reversible treatment approach.